Application of modeling and simulation in the development of protein drugs

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 2011, Issue 1, 2011, Pages 365-400

  Roskos, Lorin K ^a   Ren, Song ^a   Robbie, Gabriel ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BASILIXIMAB; BEVACIZUMAB; BIOLOGICAL PRODUCT; CYCLOPHOSPHAMIDE; DEXTRORPHAN; FIRTECAN; METHOTREXATE; MOTAVIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; OMEPRAZOLE; PACLITAXEL; PLACEBO; PROTEIN DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIMVASTATIN; TOCILIZUMAB; TRALOKINUMAB; TRASTUZUMAB; USTEKINUMAB; AS 1402; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; OTELIXIZUMAB; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; ASTHMA; BREAST CANCER; CELL KINETICS; CELL MATURATION; CELL PROLIFERATION; COMPARTMENT MODEL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; FEEDBACK SYSTEM; GOOD MANUFACTURING PRACTICE; HUMAN; LOADING DRUG DOSE; MATHEMATICAL MODEL; NEUTROPENIA; NONHUMAN; PHARMACOKINETIC PHARMACODYNAMIC MODEL; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SIMULATION; SINGLE DRUG DOSE; BODY SIZE; BREAST METASTASIS; CELL SURVIVAL; DEMOGRAPHY; DISTRIBUTION VOLUME; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG EXPOSURE; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TOLERABILITY; ENZYME KINETICS; INSULIN DEPENDENT DIABETES MELLITUS; LIGAND BINDING; MICHAELIS MENTEN KINETICS; MOLECULAR INTERACTION; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN ENGINEERING; RETICULOENDOTHELIAL SYSTEM; STEADY STATE; THEORETICAL STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 85081149308     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7415-0_17     Document Type: Article

References (65)

1. Ackerman ME, Pawlowski D, Wittrup KD (2008) Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther 7:2233-2240
2. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK et al (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61:4750-4755
3. Agoram BM (2009) Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol 67:153-160
4. Allegaert K, Anderson BJ, Naulaers G, de Hoon J, Verbesselt R, Debeer A et al (2004) Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. Eur J Clin Pharmacol 60:191-197
5. Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303-332
6. Anderson BJ, Woollard GA, Holford NH (2000) A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 50:125-134
7. Bauer RJ, Gibbons JA, Bell DP, Luo ZP, Young JD (1994) Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. J Pharmacol Exp Ther 268:152-158
8. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397-420
9. Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA et al (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333:2-13
10. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369
11. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA et al (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171-5180
12. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH (2008) Int Immunopharmacol 8(3):401-413
13. Dornhorst AC (1951) The interpretation of red cell survival curves. Blood 6:1284-1292
14. Eadie GS, Brown IW Jr (1953) Red blood cell survival studies. Blood 8:1110-1136
15. Ferl GZ, Wu AM, DiStefano JJ III (2005) A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33:1640-1652
16. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr et al (2001) Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 69:387-399
17. Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687-709
18. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573-591
19. Gueorguieva I, Clark SR, McMahon CJ, Scarth S, Rothwell NJ, Tyrrell PJ et al (2008) Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol 65:317-325
20. Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B et al (2000) Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95:2514-2522
21. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ (2007) A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63:548-561
22. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L et al (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522-2528
23. Krzyzanski W, Ramakrishnan R, Jusko WJ (1999) Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 27:467-489
24. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK (2005) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 26:295-306
25. Kuwabara T, Kobayashi S, Sugiyama Y (1996) Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 28:625-658
26. Lau Y, Wang B, Faggioni R, Lu H, Gross R, Wang Y et al (2010) Mechanistic pharmacokineticpharmacodynamic modeling of MEDI-551, a humanized IgG1 against CD19, for first-inhuman starting dose recommendation. Clin Pharmacol Ther 87(Suppl 1):S58
27. Leyland-Jones B, Colomer R, Trudeau ME, Wardley A, Latreille J, Cameron D et al (2010) Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol 28:960-966
28. Lote CJ (2000) Principles of renal physiology, 4th edn. Kluwer Academic Publishers), London.
29. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P (2009) Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68:61-76
30. Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J (2010) On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 106:195-209
31. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532
32. Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589-1596
33. Mahmood I, Green MD (2007) Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 47:1540-1554
34. Marathe A, Krzyzanski W, Mager DE (2009) Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn 36:199-219
35. Mizuno N, Kato Y, Iwamoto M, Urae A, Amamoto T, Niwa T et al (2001) Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. Pharm Res 18:1203-1209
36. Ober RJ, Radu CG, Ghetie V, Ward ES (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13:1551-1559
37. Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrel C et al (2010) An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Br J Clin Pharmacol 69:645-655
38. Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86:328-344
39. Poulin P, Theil FP (2000) A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35
40. Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370
41. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725
42. Roskos LK, Stead R, Harker L, Cheung EN (1997) A cytokinetic model of platelet production and destruction following administration of peg-rhuMGDF. Blood 90:171
43. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB (2006) Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 46:747-757
44. Roskos LK, Klakamp S, Liang M, Arends R, Green L (2007) Molecular engineering II: antibody affinity. In: Dubel S (ed) Handbook of therapeutic antibodies, 1st edn. Wiley-VCH, Weinheim, pp 145-170
45. Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D et al (2010) Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer 102:827-832
46. Savic RM, Jonker DM, Kerbusch T, Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711-726
47. Segel IH (1993) Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems. Wiley, New York
48. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028
49. Supersaxo A, Hein W, Gallati H, Steffen H (1988) Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm Res 5:472-476
50. Supersaxo A, Hein WR, Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167-169
51. Tabrizi MA, Roskos LK (2007) Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 12:540-547
52. Toon S (1996) The relevance of pharmacokinetics in the development of biotechnology products. Eur J Drug Metab Pharmacokinet 21(2):93-103
53. Uehlinger DE, Gotch FA, Sheiner LB (1992) A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51:76-89
54. Urva SR, Yang VC, Balthasar JP (2010) Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci 99:1582-1600
55. Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK (2001) Population pharmacokineticpharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn 28:321-342
56. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548-558
57. Wang DD, Zhang S, Zhao H, Men AY, Parivar K (2009) Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 49:1012-1024
58. Weinstein JN, van Osdol W (1992) The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol 14:457-463
59. Wiczling P, Rosenzweig M, Vaickus L, Jusko WJ (2010) Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjectswith psoriasis andwith type 1 diabetesmellitus. J Clin Pharmacol 50:494-506
60. Woo S, Jusko WJ (2007) Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 35:1672-1678
61. Yan X, Mager DE, Krzyzanski W (2010) Selection between Michaelis-Menten and targetmediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37:25-47
62. Yang BB, Lum PK, Hayashi MM, Roskos LK (2004) Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci 93:1367-1373
63. Zhao L, Roskos L, Griffin P, Losonsky GA, Groothius JR, Jallal B, Robbie GJ (2010) Population pharmacokinetics analysis of motavizumab in children at risk for RSV infection. Pediatric Academic Societies (PAS) annual meeting, Vancouver, Canada
64. Zhou H, Davis HM (2009) Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today 14:891-898
65. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J et al (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49:162-175